Literature DB >> 22449625

Evaluation and differential diagnosis of marked, persistent eosinophilia.

Rojelio Mejia1, Thomas B Nutman.   

Abstract

High-grade eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied. Hypereosinophilic syndromes (HES) are a group of heterogeneous disorders, many of which remain poorly defined. By definition, HES must be distinguished from other disorders with persistently elevated eosinophilia with a defined cause. Although marked eosinophilia worldwide is most commonly caused by helminth (worm) infections, non-infectious causes must be considered, and include drug reactions, malignancies, and immunologic, inflammatory and allergic diseases. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22449625      PMCID: PMC3314223          DOI: 10.1053/j.seminhematol.2012.01.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  78 in total

1.  Relative eosinophilia and functional adrenal insufficiency in critically ill patients.

Authors:  A Beishuizen; I Vermes; B S Hylkema; C Haanen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Authors:  Amy D Klion; Bruce S Bochner; Gerald J Gleich; Thomas B Nutman; Marc E Rothenberg; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2006-05-03       Impact factor: 10.793

3.  Wegener's granulomatosis with eosinophilia.

Authors:  Hirofumi Shoda; Hiroko Kanda; Ryouichi Tanaka; Yoshiaki Komagata; Yoshikata Misaki; Kazuhiko Yamamoto
Journal:  Intern Med       Date:  2005-07       Impact factor: 1.271

4.  Chronic intestinal coccidiosis in man: intestinal morphology and response to treatment.

Authors:  J S Trier; P C Moxey; E M Schimmel; E Robles
Journal:  Gastroenterology       Date:  1974-05       Impact factor: 22.682

5.  Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.

Authors:  Jeffrey A Allen; Alicia Peterson; Robert Sufit; Monique E Hinchcliff; J Matthew Mahoney; Tammara A Wood; Frederick W Miller; Michael L Whitfield; John Varga
Journal:  Arthritis Rheum       Date:  2011-11

Review 6.  Eosinophils in atopic dermatitis.

Authors:  K M Leiferman
Journal:  J Allergy Clin Immunol       Date:  1994-12       Impact factor: 10.793

Review 7.  Eosinophilia in travelers.

Authors:  P F Weller
Journal:  Med Clin North Am       Date:  1992-11       Impact factor: 5.456

Review 8.  Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature.

Authors:  P J Jederlinic; L Sicilian; E A Gaensler
Journal:  Medicine (Baltimore)       Date:  1988-05       Impact factor: 1.889

Review 9.  Cardiovascular manifestations of hypereosinophilic syndromes.

Authors:  Princess U Ogbogu; Douglas R Rosing; McDonald K Horne
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

10.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

Authors:  E A Belongia; C W Hedberg; G J Gleich; K E White; A N Mayeno; D A Loegering; S L Dunnette; P L Pirie; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

View more
  14 in total

Review 1.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

Review 2.  Eosinophilia in patients infected with human immunodeficiency virus.

Authors:  Andrew Chou; Jose A Serpa
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

3.  Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics.

Authors:  Kimberly G Blumenthal; Ilan Youngster; Dustin J Rabideau; Robert A Parker; Karen S Manning; Rochelle P Walensky; Sandra B Nelson
Journal:  J Allergy Clin Immunol       Date:  2015-05-14       Impact factor: 10.793

4.  Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS).

Authors:  Odelya E Pagovich; Katie M Stiles; Anna E Camilleri; Anthony R Russo; Saparja Nag; Ronald G Crystal
Journal:  Leukemia       Date:  2021-09-20       Impact factor: 11.528

Review 5.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

6.  Resolution of transient, marked eosinophilia, hyperimmunoglobulinemia E, and refractory eczematous dermatitis after the treatment of pancreatic pseudocysts.

Authors:  Toshiki Ito; Fumihide Iwata
Journal:  JAAD Case Rep       Date:  2015-07-31

Review 7.  Primary immunodeficiencies associated with eosinophilia.

Authors:  Behdad Navabi; Julia Elizabeth Mainwaring Upton
Journal:  Allergy Asthma Clin Immunol       Date:  2016-05-24       Impact factor: 3.406

8.  Relevance of eosinophilia and hyper-IgE in immigrant children.

Authors:  Moncef Belhassen-García; Javier Pardo-Lledías; Luis Pérez Del Villar; Antonio Muro; Virginia Velasco-Tirado; Ana Blázquez de Castro; Belen Vicente; M Inmaculada García García; Juan Luis Muñoz Bellido; Miguel Cordero-Sánchez
Journal:  Medicine (Baltimore)       Date:  2014-07       Impact factor: 1.889

Review 9.  The Biology of Eosinophils and Their Role in Asthma.

Authors:  Claire N McBrien; Andrew Menzies-Gow
Journal:  Front Med (Lausanne)       Date:  2017-06-30

10.  Eosinophilia associated with bupropion.

Authors:  Montserrat García; Borja Ruiz; Carmelo Aguirre; Esther Etxegarai; Unax Lertxundi
Journal:  Int J Clin Pharm       Date:  2013-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.